Login | Users Online: 288  
Home Print this page Email this page Small font sizeDefault font sizeIncrease font size   
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Archives | Submit article | Instructions | Subscribe | Advertise | Contact us
Year : 2021  |  Volume : 22  |  Issue : 4  |  Page : 275-279

Cardiac myosin activation in the treatment of congestive heart failure: New therapeutic options and review of literature

1 College of Medicine, University of Central Florida, Orlando, Florida, USA
2 Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA

Correspondence Address:
Dr. Arroj Ali
University of Central Florida, College of Medicine 6500 W Newberry Rd, Gainesville, FL 32605
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and Permissions

Congestive heart failure (HF) remains a major cause of cardiac-related morbidity and mortality, despite major therapeutic advancements. A newer class of medications has recently been developed which targets the root cause of HF, which is reduced myocardial contractility. This article aims to highlight the cardiac myosin activator class of drugs and the trials to date highlighting their effects on HF outcomes.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded43    
    Comments [Add]    

Recommend this journal